Navigation Links
ChanTest CEO named Distinguished Service Award recipient by the Safety Pharmacology Society
Date:7/24/2013

CLEVELAND, July 24, 2013 /PRNewswire/ -- ChanTest proudly announces that CEO, President and Founder, Arthur "Buzz" Brown, M.D., Ph.D. has been named the recipient of the prestigious Distinguished Service Award by the Safety Pharmacology Society (SPS).  The following statement was issued by the SPS, "The award is in recognition of Dr. Brown's significant scientific contributions to many areas of Safety Pharmacology, most notably contributions to ion channels and their relationship to human disease."

(Photo: http://photos.prnewswire.com/prnh/20130724/CL50851 )

The SPS will officially present the award at the 13th SPS Annual Meeting in Rotterdam, The Netherlands.  As part of the ceremony, Dr. Brown will present a talk entitled, "Predicting Cardiac Safety: From Molecules to Man" on Thursday, September 19, 2013 from 11:30–12:00 at the Congress Centre de Doelen in Rotterdam.

Dr. Brown's establishment of ChanTest in 1998 allowed pharma and biotech companies to outsource important and unique safety pharmacology studies that have proven difficult and costly to implement "in-house".  To this date, Dr. Brown's lab team at ChanTest continues to provide cutting edge assays that serve the Safety Pharmacology industry.

Dr. Brown collaborates with the US Federal Drug Administration (FDA) on cardiac safety issues and he holds nine patents on ion channel pharmacology, therapeutics and devices.

"I am honored to receive this award," said Dr. Brown.  "The Safety Pharmacology Society has played a key role in the making of better and safer medicines by the pharmaceutical industry." 

For more details about Dr. Brown's career, click here.

About ChanTest – The Ion Channel Expert
ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 300 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 


'/>"/>
SOURCE ChanTest Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
2. ChanTest hires Chris Mathes as Chief Commercial Officer
3. Roger Graham Named President of Mylan Specialty
4. Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings
5. Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS
6. Baby Eva Named After Pioneering IVF Test
7. Comprehensive Care Corporation CEO Clark A. Marcus Named to Board of Americas Agenda: Health Care for All
8. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
9. Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year
10. RenovoRx Named Winner of 2013 TiE50 "Top Startup"
11. Wyle Aided System Gets Named to Space Technology Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):